Herpes Zoster Infections in SLE in a University Hospital in Saudi Arabia: Risk Factors and Outcomes

Table 2

SLE treatment at the time of Zoster infection in relation to SLE activity.

SLE treatment	Active SLE (𝑛=9)𝑁 (%)	SLE in remission (𝑛=23) 𝑁 (%)	𝑃 value
MPSL	3 (88.9)	8 (34.7)	.0007^∗
Cyclo IV	7 (77.8)	7 (30.4)	.0086^∗
AZA	6 (66.7)	8 (34.8)	.0964^∗
MMF	6 (66.7)	0 (0.0)	.0002^∗

∗significant (𝑃<.05), Cylo IV: intravenous cyclophosphamide, MPSL:methyl prednisolone, AZA: azathioprine, MMF: mycophenolate, mofetil Oral PSL: (Oral prednisolone).
(All patients (100%) received oral prednisolone. The mean dose in active SLE cases was 80±3 mg and in patients with SLE in remission was 12.2±1 mg).